Ani Pharmaceuticals Stock Operating Margin

ANIP Stock

USD 64.26 0.09 0.14%

ANI Pharmaceuticals fundamentals help investors to digest information that contributes to ANI Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of ANI Stock. The fundamental analysis module provides a way to measure ANI Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ANI Pharmaceuticals stock.

Last Reported

Projected for Next Year

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

ANI Pharmaceuticals Company Operating Margin Analysis

ANI Pharmaceuticals' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.

Operating Margin

Operating Income

Revenue

100

More About Operating Margin | All Equity Analysis

Current ANI Pharmaceuticals Operating Margin

0.01 %

Most of ANI Pharmaceuticals' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ANI Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

ANI Operating Margin Driver Correlations

Understanding the fundamental principles of building solid financial models for ANI Pharmaceuticals is extremely important. It helps to project a fair market value of ANI Stock properly, considering its historical fundamentals such as Operating Margin. Since ANI Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ANI Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ANI Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Common Stock	Short Term Debt	Short Term Investments	Current Deferred Revenue	Net Receivables	Net Tangible Assets	Long Term Debt	Good Will	Long Term Debt Total	Long Term Investments	Treasury Stock	Intangible Assets	Property Plant Equipment	Capital Surpluse	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock	Accumulated Depreciation
Total Assets		0.96	0.7	0.0	0.97	0.99	0.96	-0.42	-0.22	0.17	0.69	0.98	0.18	0.97	0.94	0.62	0.75	-0.74	0.96	0.87	0.83	-0.74	0.85	0.75	0.82	-0.77
Total Stockholder Equity	0.96		0.69	0.07	0.93	0.91	0.97	-0.47	-0.17	0.17	0.68	0.95	0.21	0.89	0.86	0.69	0.57	-0.79	0.87	0.89	0.9	-0.76	0.81	0.8	0.85	-0.78
Net Debt	0.7	0.69		0.24	0.62	0.68	0.53	-0.47	-0.28	0.3	0.29	0.75	-0.38	0.62	0.55	0.59	0.34	-0.82	0.77	0.86	0.67	-0.78	0.47	0.37	0.55	-0.44
Retained Earnings	0.0	0.07	0.24		-0.15	-0.03	-0.05	-0.86	0.41	0.27	0.01	-0.04	-0.2	-0.05	-0.2	0.15	-0.18	-0.18	0.06	0.18	0.02	-0.06	-0.21	-0.24	-0.21	0.25
Accounts Payable	0.97	0.93	0.62	-0.15		0.96	0.96	-0.3	-0.36	0.25	0.64	0.98	0.27	0.94	0.96	0.57	0.74	-0.74	0.88	0.83	0.83	-0.73	0.88	0.83	0.87	-0.86
Total Liab	0.99	0.91	0.68	-0.03	0.96		0.93	-0.38	-0.24	0.17	0.68	0.97	0.17	0.99	0.96	0.56	0.83	-0.69	0.97	0.83	0.77	-0.71	0.84	0.7	0.77	-0.73
Total Current Assets	0.96	0.97	0.53	-0.05	0.96	0.93		-0.39	-0.19	0.14	0.74	0.94	0.37	0.92	0.91	0.61	0.67	-0.68	0.84	0.8	0.85	-0.7	0.85	0.83	0.85	-0.83
Common Stock	-0.42	-0.47	-0.47	-0.86	-0.3	-0.38	-0.39		-0.2	-0.32	-0.38	-0.4	-0.01	-0.37	-0.27	-0.43	-0.15	0.43	-0.42	-0.48	-0.42	0.36	-0.23	-0.21	-0.26	0.22
Short Term Debt	-0.22	-0.17	-0.28	0.41	-0.36	-0.24	-0.19	-0.2		-0.33	0.11	-0.33	0.1	-0.24	-0.33	-0.22	-0.18	0.33	-0.19	-0.28	-0.25	0.61	-0.34	-0.48	-0.4	0.34
Short Term Investments	0.17	0.17	0.3	0.27	0.25	0.17	0.14	-0.32	-0.33		-0.17	0.26	0.03	0.15	0.18	-0.02	0.06	-0.42	0.14	0.35	0.28	-0.27	0.24	0.23	0.28	-0.2
Current Deferred Revenue	0.69	0.68	0.29	0.01	0.64	0.68	0.74	-0.38	0.11	-0.17		0.65	0.31	0.7	0.66	0.39	0.56	-0.18	0.62	0.34	0.56	-0.37	0.59	0.6	0.55	-0.74
Net Receivables	0.98	0.95	0.75	-0.04	0.98	0.97	0.94	-0.4	-0.33	0.26	0.65		0.15	0.95	0.94	0.62	0.71	-0.79	0.93	0.89	0.85	-0.78	0.85	0.78	0.85	-0.82
Net Tangible Assets	0.18	0.21	-0.38	-0.2	0.27	0.17	0.37	-0.01	0.1	0.03	0.31	0.15		0.25	0.3	0.07	0.2	0.07	-0.02	-0.02	0.21	0.08	0.3	0.38	0.33	-0.35
Long Term Debt	0.97	0.89	0.62	-0.05	0.94	0.99	0.92	-0.37	-0.24	0.15	0.7	0.95	0.25		0.97	0.56	0.85	-0.62	0.95	0.78	0.75	-0.68	0.84	0.72	0.77	-0.72
Good Will	0.94	0.86	0.55	-0.2	0.96	0.96	0.91	-0.27	-0.33	0.18	0.66	0.94	0.3	0.97		0.47	0.85	-0.58	0.9	0.73	0.75	-0.62	0.89	0.77	0.84	-0.78
Long Term Debt Total	0.62	0.69	0.59	0.15	0.57	0.56	0.61	-0.43	-0.22	-0.02	0.39	0.62	0.07	0.56	0.47		0.3	-0.66	0.55	0.69	0.76	-0.74	0.58	0.63	0.6	-0.44
Long Term Investments	0.75	0.57	0.34	-0.18	0.74	0.83	0.67	-0.15	-0.18	0.06	0.56	0.71	0.2	0.85	0.85	0.3		-0.31	0.8	0.46	0.47	-0.35	0.78	0.51	0.53	-0.49
Treasury Stock	-0.74	-0.79	-0.82	-0.18	-0.74	-0.69	-0.68	0.43	0.33	-0.42	-0.18	-0.79	0.07	-0.62	-0.58	-0.66	-0.31		-0.69	-0.97	-0.76	0.81	-0.57	-0.53	-0.64	0.54
Intangible Assets	0.96	0.87	0.77	0.06	0.88	0.97	0.84	-0.42	-0.19	0.14	0.62	0.93	-0.02	0.95	0.9	0.55	0.8	-0.69		0.84	0.72	-0.69	0.76	0.59	0.69	-0.62
Property Plant Equipment	0.87	0.89	0.86	0.18	0.83	0.83	0.8	-0.48	-0.28	0.35	0.34	0.89	-0.02	0.78	0.73	0.69	0.46	-0.97	0.84		0.82	-0.83	0.67	0.6	0.72	-0.58
Capital Surpluse	0.83	0.9	0.67	0.02	0.83	0.77	0.85	-0.42	-0.25	0.28	0.56	0.85	0.21	0.75	0.75	0.76	0.47	-0.76	0.72	0.82		-0.75	0.87	0.86	0.93	-0.73
Short Long Term Debt	-0.74	-0.76	-0.78	-0.06	-0.73	-0.71	-0.7	0.36	0.61	-0.27	-0.37	-0.78	0.08	-0.68	-0.62	-0.74	-0.35	0.81	-0.69	-0.83	-0.75		-0.6	-0.69	-0.68	0.58
Net Invested Capital	0.85	0.81	0.47	-0.21	0.88	0.84	0.85	-0.23	-0.34	0.24	0.59	0.85	0.3	0.84	0.89	0.58	0.78	-0.57	0.76	0.67	0.87	-0.6		0.89	0.91	-0.74
Net Working Capital	0.75	0.8	0.37	-0.24	0.83	0.7	0.83	-0.21	-0.48	0.23	0.6	0.78	0.38	0.72	0.77	0.63	0.51	-0.53	0.59	0.6	0.86	-0.69	0.89		0.92	-0.81
Capital Stock	0.82	0.85	0.55	-0.21	0.87	0.77	0.85	-0.26	-0.4	0.28	0.55	0.85	0.33	0.77	0.84	0.6	0.53	-0.64	0.69	0.72	0.93	-0.68	0.91	0.92		-0.8
Accumulated Depreciation	-0.77	-0.78	-0.44	0.25	-0.86	-0.73	-0.83	0.22	0.34	-0.2	-0.74	-0.82	-0.35	-0.72	-0.78	-0.44	-0.49	0.54	-0.62	-0.58	-0.73	0.58	-0.74	-0.81	-0.8

Click cells to compare fundamentals

A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.

Competition

Predict ANI Pharmaceuticals

Operating Profit Margin Over Time

ANI Pretax Profit Margin

Pretax Profit Margin

(0.038)

At this time, ANI Pharmaceuticals' Pretax Profit Margin is relatively stable compared to the past year.

Based on the recorded statements, ANI Pharmaceuticals has an Operating Margin of 0.008%. This is 100.02% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The operating margin for all United States stocks is 100.15% lower than that of the firm.

ANI Operating Margin Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ANI Pharmaceuticals' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ANI Pharmaceuticals could also be used in its relative valuation, which is a method of valuing ANI Pharmaceuticals by comparing valuation metrics of similar companies.

ANI Pharmaceuticals is currently under evaluation in operating margin category among its peers.

ANI Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, ANI Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to ANI Pharmaceuticals' managers, analysts, and investors.

Environmental

Governance

Social

ANI Fundamentals

	Return On Equity	-0.0418
	Return On Asset	0.0084
	Profit Margin	(0.03) %
	Operating Margin	0.01 %
	Current Valuation	1.91 B
	Shares Outstanding	21.76 M
	Shares Owned By Insiders	11.22 %
	Shares Owned By Institutions	97.41 %
	Number Of Shares Shorted	2.56 M
	Price To Earning	43.35 X
	Price To Book	3.50 X
	Price To Sales	2.28 X
	Revenue	614.38 M
	Gross Profit	364.17 M
	EBITDA	63.12 M
	Net Income	(18.52 M)
	Cash And Equivalents	63.38 M
	Cash Per Share	3.89 X
	Total Debt	314.98 M
	Debt To Equity	0.85 %
	Current Ratio	3.35 X
	Book Value Per Share	20.54 X
	Cash Flow From Operations	64.02 M
	Short Ratio	11.31 X
	Earnings Per Share	(1.04) X
	Price To Earnings To Growth	1.06 X
	Target Price	81.5
	Number Of Employees	897
	Beta	0.63
	Market Capitalization	1.4 B
	Total Asset	1.28 B
	Retained Earnings	(100.28 M)
	Working Capital	334 M
	Current Asset	192.58 M
	Current Liabilities	11.76 M
	Net Asset	1.28 B

About ANI Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze ANI Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ANI Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ANI Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Additional Tools for ANI Stock Analysis

When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC